BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38008041)

  • 1. Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells.
    Zhou Z; Fan H; Yu D; Shi F; Li Q; Zhang Z; Wang X; Zhang X; Dong C; Sun H; Mi W
    Bioorg Med Chem; 2023 Dec; 96():117526. PubMed ID: 38008041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment.
    Xie B; Xu B; Xin L; Wei Y; Guo X; Dong C
    Bioorg Chem; 2023 Aug; 137():106590. PubMed ID: 37163809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
    Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
    Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.
    Hayhow TG; Williamson B; Lawson M; Cureton N; Braybrooke EL; Campbell A; Carbajo RJ; Cheraghchi-Bashi A; Chiarparin E; Diène CR; Fallan C; Fisher DI; Goldberg FW; Hopcroft L; Hopcroft P; Jackson A; Kettle JG; Klinowska T; Künzel U; Lamont G; Lewis HJ; Maglennon G; Martin S; Gutierrez PM; Morrow CJ; Nikolaou M; Nissink JWM; O'Shea P; Polanski R; Schade M; Scott JS; Smith A; Weber J; Wilson J; Yang B; Crafter C
    Commun Biol; 2024 May; 7(1):563. PubMed ID: 38740899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
    Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
    Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
    Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
    Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance.
    Lin X; Xiang H; Luo G
    Eur J Med Chem; 2020 Nov; 206():112689. PubMed ID: 32829249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
    Luo G; Li X; Lin X; Lu X; Li Z; Xiang H
    J Steroid Biochem Mol Biol; 2022 Oct; 223():106154. PubMed ID: 35870675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
    Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
    J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α.
    Jiang Y; Deng Q; Zhao H; Xie M; Chen L; Yin F; Qin X; Zheng W; Zhao Y; Li Z
    ACS Chem Biol; 2018 Mar; 13(3):628-635. PubMed ID: 29271628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
    Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
    Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTAC Degrader of Estrogen Receptor α Targeting DNA-Binding Domain in Breast Cancer.
    Zhang X; Zhang Z; Xue X; Fan T; Tan C; Liu F; Tan Y; Jiang Y
    ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1109-1118. PubMed ID: 36407946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
    He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
    J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Selective Target Degradation by Folate-Caged PROTACs.
    Liu J; Chen H; Liu Y; Shen Y; Meng F; Kaniskan HÜ; Jin J; Wei W
    J Am Chem Soc; 2021 May; 143(19):7380-7387. PubMed ID: 33970635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microneedle Patch Delivery of PROTACs for Anti-Cancer Therapy.
    Cheng X; Hu S; Cheng K
    ACS Nano; 2023 Jun; 17(12):11855-11868. PubMed ID: 37294705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
    Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Optimization of Decoy Oligonucleotide-Based PROTAC That Degrades the Estrogen Receptor.
    Naganuma M; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
    Bioconjug Chem; 2023 Oct; 34(10):1780-1788. PubMed ID: 37736001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer.
    Grinshpun A
    Curr Opin Oncol; 2023 Nov; 35(6):472-478. PubMed ID: 37427531
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.